TD Cowen Maintains Outperform on CVS Health, Lowers Price Target to $99
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Charles Ryhee has maintained an Outperform rating on CVS Health (NYSE:CVS) but has reduced the price target from $102 to $99.
December 11, 2023 | 4:32 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
TD Cowen analyst Charles Ryhee reaffirmed an Outperform rating on CVS Health but lowered the price target to $99, indicating a positive outlook with a slightly reduced growth expectation.
The maintenance of an Outperform rating suggests that the analyst continues to have a positive view on CVS Health's future performance. However, the reduction in the price target could imply a more conservative view on the growth prospects or valuation of the company. This news is likely to be seen as mildly negative by investors, as it suggests a slight decrease in expected future stock performance. However, since the rating remains positive, the overall impact on the stock price may be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100